NexTechie BioFlux - The Brief: PROTAC Approval, Lilly’s Major Acquisitions, and Alzheimer’s Care Standard Shifts

The biotech industry is entering a transformative era, marked by three landmark developments. First, the FDA’s historic approval of Veppanu, the first-ever PROTAC therapy, validates protein degradation as a powerful new therapeutic modality. Simultaneously, Eli Lilly is executing a massive $21 billion M and A campaign, acquiring next-generation platforms like in vivo CAR-T to secure its future beyond current blockbusters. Finally, Axsome’s Auvelity sets a safer standard in Alzheimer’s care as the first non-antipsychotic treatment for agitation. Together, these events signal a strategic shift toward precision medicine and advanced technologies that address previously untreatable biological challenges.Subscribe to the paid version of NexTechie BioFlux Newsletter on Patreon to gain full access to a Detailed Video and the full Newsletter in English. NexTechie Premium: https://vip.nextechie.in Statutory Declaration: Artificial Intelligence has been utilized within the editorial workflow and in the production of audio and video content, under strict human oversight and comprehensive editorial guidance.